Tenderwize
Wróć do wyszukiwania

Open-house rebate agreement for testosterone injection solution

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Nov 03, 2027 · 432 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Testosteron in der Darreichungsform Injektionslösung, ATC G03BA03

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

The notice repeatedly states that the arrangement is an open-house model and not a normal procurement procedure, which...

Paper submissions must be sent in duplicate originals, and electronic submissions must use the DTVP communication area...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Dec 2027
  • Non-exclusive rebate agreements for pharmaceutical products concerning testosterone in injection solution form, ATC G03BA03.
  • Open-house model with identical, non-negotiable contract terms for all qualifying pharmaceutical companies.
Pokaż pełne podsumowanie

This is an open-house pharmaceutical supply arrangement by AOK Bayern for testosterone injection solution (ATC G03BA03), not a competitive award procedure in the usual sense. The buyer states that it will conclude identical, non-exclusive rebate agreements with all interested pharmaceutical companies that meet the stated suitability requirement. Contracting is possible from 2026-01-01 until 2027-11-03, with contracts ending on 2027-12-31. Submission is via DTVP electronic portal with qualified electronic signature or by signed paper originals in duplicate; German language is required, and non-German documents need German translation.

Ryzyka

The notice repeatedly states that the arrangement is an open-house model and not a normal procurement procedure, which...

Paper submissions must be sent in duplicate originals, and electronic submissions must use the DTVP communication area...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
  • The signed contract and the completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be submitted.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreement for testosterone injection solution

Single lot covering non-exclusive open-house rebate agreements for the medicinal product testosterone in injection solution form, ATC G03BA03. The notice says the contract terms are fixed and not individually negotiable. Place of performance is Germany, Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Dec 2025 - Dec 2027

Kategoria

Pharmaceutical products

Termin

Deadline Nov 03, 2027

Szczegóły zamówienia

Data publikacji
16 Nov 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
759950-2025

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30